NUTEK OIDO
Redefining precision in Surgical Oncology, on-the-body cancer tissue detection, during operation
Company Overview
Snapshot
Founded in June 2019 by Dov Cohen, Ofer Braun, and Prof. MD. Hanoch Kashtan, NUTEK OIDO operates with 1–10 employees. The company has raised $1.78M across 6 funding rounds. In March 2023, NUTEK OIDO secured a grant from the FFG - Austrian Federal Innovation Authority, highlighting its focus on advanced medical technology.
Business overview
NUTEK OIDO is dedicated to enhancing precision in surgical oncology by developing solutions for real-time, on-the-body cancer tissue detection during operations. The company's core product is the "Rainbow Probe," a high-resolution hyperspectral imaging handheld device designed to guide surgeons in identifying and removing residual cancer tissue. Initially focused on breast cancer, NUTEK OIDO aims to address the issue of undetected cancer cells that lead to recurrence and repeated treatments. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices, serving hospitals, healthcare organizations, and insurance companies globally.
Strategic signal
In July 2024, NUTEK OIDO was featured in news reports for its innovative approach to identifying remaining cancer cells using space technology. This highlights the company's strategic validation through advanced technological adoption and its potential to significantly impact real-time cancer diagnostics, signaling strong innovation and growth potential to investors.
Company Intelligence Q&A
- What is NUTEK OIDO's primary technological innovation?
- NUTEK OIDO's primary innovation is the "Rainbow Probe," a high-resolution hyperspectral imaging handheld device that enables surgeons to detect residual cancer tissue on the patient's body during surgery, guiding immediate removal.
- When was NUTEK OIDO founded and by whom?
- NUTEK OIDO was founded in June 2019 by Dov Cohen, Ofer Braun, and Prof. MD. Hanoch Kashtan.
- Has NUTEK OIDO received any significant grants recently?
- In March 2023, NUTEK OIDO secured a grant from the FFG - Austrian Federal Innovation Authority. Additionally, in February 2023, the company received a grant from the European Space Agency Business Incubator.
- What recognition has NUTEK OIDO received for its innovation?
- In December 2020, NUTEK OIDO won the first prize at the Paul Merage Institute startup competition for its innovative approach to cancer detection.
- What is the primary medical application of NUTEK OIDO's technology?
- NUTEK OIDO's initial application for its NOAM Rainbow Probe is in breast cancer surgery, with plans to expand to other high-precision and minimally invasive cancer surgical interventions.